4.6 Article

ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation

期刊

JOURNAL OF PHYSIOLOGY-LONDON
卷 593, 期 18, 页码 4181-4199

出版社

WILEY
DOI: 10.1113/JP270358

关键词

-

资金

  1. Italian Department of Health [GR-2009-1580433]
  2. Italian Telethon Foundation [GGP10101, GGP14096]

向作者/读者索取更多资源

Myotonia congenita is an inherited disease caused by loss-of-function mutations of the skeletal muscle ClC-1 chloride channel, characterized by impaired muscle relaxation after contraction and stiffness. In the present study, we provided an in-depth characterization of F484L, a mutation previously identified in dominant myotonia, in order to define the genotype-phenotype correlation, and to elucidate the contribution of this pore residue to the mechanisms of ClC-1 gating. Patch-clamp recordings showed that F484L reduced chloride currents at every tested potential and dramatically right-shifted the voltage dependence of slow gating, thus contributing to the mild clinical phenotype of affected heterozygote carriers. Unlike dominant mutations located at the dimer interface, no dominant-negative effect was observed when F484L mutant subunits were co-expressed with wild type. Molecular dynamics simulations further revealed that F484L affected the slow gate by increasing the frequency and stability of the H-bond formation between the pore residue E232 and the R helix residue Y578. In addition, using patch-clamp electrophysiology, we characterized three other myotonic ClC-1 mutations. We proved that the dominant L198P mutation in the channel pore also right-shifted the voltage dependence of slow gating, recapitulating mild myotonia. The recessive V640G mutant drastically reduced channel function, which probably accounts for myotonia. In contrast, the recessive L628P mutant produced currents very similar to wild type, suggesting that the occurrence of the compound truncating mutation (Q812X) or other muscle-specific mechanisms accounted for the severe symptoms observed in this family. Our results provide novel insight into the molecular mechanisms underlying normal and altered ClC-1 function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Artificial intelligence-driven identification of morin analogues acting as CaV1.2 channel blockers: Synthesis and biological evaluation

Gabriele Carullo, Federica Falbo, Amer Ahmed, Alfonso Trezza, Beatrice Gianibbi, Orazio Nicolotti, Giuseppe Campiani, Francesca Aiello, Simona Saponara, Fabio Fusi

Summary: Three new derivatives (5a-c) that interact with Ca(V)1.2 channels were found using PLATO. These derivatives exhibited better vasorelaxant effects than the parent compound and antagonized electro- and pharmaco-mechanical coupling in an endothelium-independent manner. Compound 5a, the most potent in the series, also reduced Ca2+ mobilization and inhibited Ba2+ current through Ca(V)1.2 channels, but it also inhibited K(Ca)1.1 channel currents in a concentration-dependent manner.

BIOORGANIC CHEMISTRY (2023)

Article Clinical Neurology

Integrative miRNA-mRNA profiling of human epidermis: unique signature of SCN9A painful neuropathy

Mirna Andelic, Erika Salvi, Stefania Marcuzzo, Margherita Marchi, Raffaella Lombardi, Daniele Cartelli, Daniele Cazzato, Elkadia Mehmeti, Andrea Gelemanovic, Matilde Paolini, Carlotta Pardo, Ilaria D'Amato, Janneke G. J. Hoeijmakers, Sulayman Dib-Hajj, Stephen G. Waxman, Catharina G. Faber, Giuseppe Lauria

Summary: Personalized management of neuropathic pain is a clinical need that has not been fulfilled due to various factors. Recent studies on microRNA have provided insights into pain-related mechanisms and identified potential drug candidates. By generating a molecular profile of the epidermis in patients with sodium channel-related painful neuropathy, the researchers identified specific miRNAs and mRNA targets that are involved in peripheral sensory transduction and modulation. The findings suggest a complex interaction between epidermal cells and axons in neuropathy pain. This targeted molecular profiling could advance personalized medicine for neuropathic pain.
Letter Clinical Neurology

Reply to the Letter to the Editor in response to Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Chemistry, Medicinal

TIRESIA: An eXplainable Artificial Intelligence Platform for Predicting Developmental Toxicity

Maria Vittoria Togo, Fabrizio Mastrolorito, Fulvio Ciriaco, Daniela Trisciuzzi, Anna Rita Tondo, Nicola Gambacorta, Loredana Bellantuono, Alfonso Monaco, Francesco Leonetti, Roberto Bellotti, Cosimo Damiano Altomare, Nicola Amoroso, Orazio Nicolotti

Summary: This article presents a robust and reproducible eXplainable Artificial Intelligence (XAI) approach for predicting developmental toxicity, which is a challenging human-health endpoint in toxicology. The proposed framework compares favorably with state-of-the-art approaches in terms of accuracy, sensitivity, and specificity, providing a reliable support system for ensuring informativeness, uncertainty estimation, generalization, and transparency in developmental toxicity. The model utilizes specific molecular descriptors and structural alerts to distinguish toxic and nontoxic chemicals.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2023)

Article Biochemistry & Molecular Biology

Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis

Christos Stergiou, Rhys Williams, Jennifer R. R. Fleming, Vasiliki Zouvelou, Elpinickie Ninou, Francesca Andreetta, Elena Rinaldi, Ornella Simoncini, Renato Mantegazza, Julius Bogomolovas, John Tzartos, Siegfried Labeit, Olga Mayans, Socrates Tzartos

Summary: Myasthenia gravis is an autoimmune disease caused by antibodies targeting the neuromuscular junction of skeletal muscles. The major autoantigen is nicotinic acetylcholine receptor. Thymus and thymoma play critical roles in the mechanisms and management of the disease. This study focused on the localization of titin epitopes to develop more specific anti-titin diagnostics.

BIOMEDICINES (2023)

Article Neurosciences

Coexistence of SCN4A and CLCN1 mutations in a family with atypical myotonic features: A clinical and functional study

Veria Vacchiano, Raffaella Brugnoni, Carmen Campanale, Paola Imbrici, Giorgia Dinoi, Eleonora Canioni, Paola Laghetti, Ilaria Saltarella, Concetta Altamura, Lorenzo Maggi, Rocco Liguori, Vincenzo Donadio, Jean-Francois Desaphy

Summary: Non-dystrophic myotonias are a group of diseases characterized by muscle stiffness caused by gene mutations in CLCN1 and SCN4A. In this study, the clinical features and genetic variants of five affected relatives were described. Functional experiments revealed that the p.K1302R variant in SCN4A and the p.H838P variant in CLCN1 caused mild changes in sodium and chloride currents, respectively, leading to the mixed myotonic phenotypes observed in the patients. Mexiletine and lamotrigine were found to be effective in treating patients carrying the p.K1302R variant.

EXPERIMENTAL NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

MiR-146a in ALS: Contribution to Early Peripheral Nerve Degeneration and Relevance as Disease Biomarker

Eleonora Giagnorio, Claudia Malacarne, Paola Cavalcante, Letizia Scandiffio, Marco Cattaneo, Viviana Pensato, Cinzia Gellera, Nilo Riva, Angelo Quattrini, Eleonora Dalla Bella, Giuseppe Lauria, Renato Mantegazza, Silvia Bonanno, Stefania Marcuzzo

Summary: Amyotrophic lateral sclerosis (ALS) is characterized by the loss of upper and lower motor neurons (UMNs, LMNs) and miR-146a dysregulation may contribute to the pathogenesis of ALS. In this study, miR-146a levels were increased in ALS peripheral nerves and decreased in the serum of ALS patients, suggesting its potential as a diagnostic and prognostic biomarker for the disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Genetic Profiling of Sodium Channels in Diabetic Painful and Painless and Idiopathic Painful and Painless Neuropathies

Rowida Almomani, Maurice Sopacua, Margherita Marchi, Milena Sleczkowska, Patrick Lindsey, Bianca T. A. de Greef, Janneke G. J. Hoeijmakers, Erika Salvi, Ingemar S. J. Merkies, Maryam A. Ferdousi, Rayaz Malik, Dan Ziegler, Kasper W. J. Derks, Gidon Boenhof, Filippo Martinelli-Boneschi, Daniele Cazzato, Raffaella Lombardi, Sulayman G. Dib-Hajj, Stephen Waxman, Hubert J. M. M. Smeets, Monique G. Gerrits, Catharina Faber, Giuseppe Lauria

Summary: Rare SCG genetic variants may contribute to the development of painful neuropathy. Genetic profiling and SCG variant identification can provide better understanding of the genetic variability in patients with painful and painless neuropathy, leading to improved risk stratification and personalized pain treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Anesthesiology

TRPA1 rare variants in chronic neuropathic and nociplastic pain patients

Margherita Marchi, Erika Salvi, Mirna Andelic, Elkadia Mehmeti, Ilaria D'Amato, Daniele Cazzato, Federica Chiappori, Raffaella Lombardi, Daniele Cartelli, Grazia Devigili, Eleonora Dalla Bella, Monique Gerrits, Rowida Almomani, Rayaz A. Malik, Milena Sleczkowska, Anna Mazzeo, Luca Gentile, Sulayman Dib-Hajj, Stephen G. Waxman, Catharina G. Faber, Eleonora Vecchio, Marina de Tommaso, Giuseppe Lauria

Summary: This study aimed to identify rare variants associated with chronic neuropathic pain and nociplastic pain by conducting next-generation sequencing and gene-wise aggregation analysis. TRPA1 was found to be the most significant gene, with the frequency of rare variants significantly differentiating chronic pain patients from healthy controls. The study expands the understanding of channelopathy-related chronic pain disorders and contributes to personalized therapies based on patients' molecular profiles.
Article Biochemistry & Molecular Biology

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization

Nicola Iacomino, Letizia Scandiffio, Fabio Conforti, Erika Salvi, Maria Cristina Tarasco, Federica Bortone, Stefania Marcuzzo, Ornella Simoncini, Francesca Andreetta, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Carlo Antozzi, Renato Mantegazza, Tommaso Martino De Pas, Paola Cavalcante

Summary: The thymus plays a role in the development of autoimmunity in myasthenia gravis (MG) patients. Changes in gene expression related to muscle autoantigens, such as AChR α subunit (CHRNA1) and autoimmune regulator (AIRE), as well as tumor-related muscle-like proteins (NEFM, HSP60, RYR1, RYR3, TTN), were observed in MG thymuses with hyperplasia and thymoma. These findings suggest a potential mechanism for the development of MG in thymomas involving altered autoantigen expression and molecular mimicry.

BIOMEDICINES (2023)

Article Immunology

Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies

Cristina Cappelletti, Raffaella Brugnoni, Silvia Bonanno, Francesca Andreetta, Franco Salerno, Eleonora Canioni, Gaetano Nicola Alfio Vattemi, Paola Tonin, Renato Mantegazza, Lorenzo Maggi

Summary: This study aimed to investigate whether the immune system could serve as a source of potential biomarkers for stratifying immune-mediated necrotizing myopathies (IMNMs) subtypes. The results showed a significant preponderance of M1 macrophages in muscle samples of both SRP+ and HMGCR(+) IMNM patients. Furthermore, TLR4 and IL-7 were identified as potential immune biomarkers for differentiating between SRP+ and HMGCR+ patients.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Article Chemistry, Medicinal

CIRCE: Web-Based Platform for the Prediction of Cannabinoid Receptor Ligands Using Explainable Machine Learning

Nicola Gambacorta, Fulvio Ciriaco, Nicola Amoroso, Cosimo Damiano Altomare, Ju''rgen Bajorath, Orazio Nicolotti

Summary: In this study, a CIRCE compound prediction platform was developed based on explainable machine learning to support the design of selective CB1R and CB2R ligands. The platform achieved about 80% accuracy in test calculations and provided rationalized explanations for the predictions. CIRCE is freely available as a web-based prediction platform.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2023)

Article Biochemistry & Molecular Biology

Investigation on Novel E/Z 2-Benzylideneindan-1-One-Based Photoswitches with AChE and MAO-B Dual Inhibitory Activity

Marco Paolino, Modesto de Candia, Rosa Purgatorio, Marco Catto, Mario Saletti, Anna Rita Tondo, Orazio Nicolotti, Andrea Cappelli, Antonella Brizzi, Claudia Mugnaini, Federico Corelli, Cosimo D. Altomare

Summary: Combining photopharmacology approach with multitarget-directed ligand design strategy, a novel donepezil-like compound was discovered that showed dual inhibition activity against acetylcholinesterase and monoamine oxidase B, two target enzymes related to Alzheimer's disease. Further investigation of similar compounds revealed different selectivity towards the target enzymes.

MOLECULES (2023)

Review Genetics & Heredity

Novel HSPG2 Gene Mutation Causing Schwartz-Jampel Syndrome in a Moroccan Family: A Literature Review

Raffaella Brugnoni, Daria Marelli, Nicola Iacomino, Eleonora Canioni, Cristina Cappelletti, Lorenzo Maggi, Anna Ardissone

Summary: Schwartz-Jampel syndrome type 1 (SJS1) is a rare genetic disorder caused by mutations in the HSPG2 gene, resulting in musculoskeletal problems. This study reports two mutations in a Moroccan child with SJS1 and analyzes the clinical features and genetic characteristics of the disease.
Review Health Care Sciences & Services

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis

Carlo Antozzi, Renato Mantegazza

Summary: Myasthenia gravis is an autoimmune disorder that causes muscle weakness and fatigue. Standard therapies have limitations and there is a need for targeted treatments. Ravulizumab, a long-acting complement inhibitor, has shown effective and sustained improvement in patients with myasthenia gravis.

PATIENT-RELATED OUTCOME MEASURES (2023)

暂无数据